Valaciclovir

Generic Name
Valaciclovir
Brand Names
Valtrex
Drug Type
Small Molecule
Chemical Formula
C13H20N6O4
CAS Number
124832-26-4
Unique Ingredient Identifier
MZ1IW7Q79D
Background

Valaciclovir (valacyclovir), also known as Valtrex, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 and marketed by GlaxoSmithKline . Valacyclovir is the L-valine ester of aciclovir. It is a member of the purine (guanine) nucleoside analog drug class ...

Indication

Valacyclovir is a nucleoside analog DNA polymerase inhibitor indicated for :

Adults

• Cold Sores (Herpes Labialis)

• Genital Herpes

• Treatment of genital herpes lesions in immunocompetent patients (initial or recurrent episode)

• Suppression of genital herpes lesions in immunocompetent or HIV-infected patients

• Reduction of viral transmission
...

Associated Conditions
Chickenpox, Genital Herpes, Genital herpes, initial episode, Herpes Labialis, Herpes Zoster, Recurrent Genital Herpes (RGH)
Associated Therapies
Suppression of Recurrent Genital Herpes (RGH)
Clinical Trials
Related News

VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

Phase 4
Completed
Conditions
Herpes Labialis
First Posted Date
2006-03-23
Last Posted Date
2018-03-23
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
70
Registration Number
NCT00306293
Locations
🇺🇸

GSK Investigational Site, Memphis, Tennessee, United States

A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children

Phase 1
Completed
Conditions
Herpes Simplex
Interventions
Drug: Valaciclovir
First Posted Date
2006-02-28
Last Posted Date
2017-09-11
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
36
Registration Number
NCT00297206
Locations
🇿🇦

GSK Investigational Site, George, South Africa

Controlled Trial of Valacyclovir in Infectious Mononucleosis

Phase 1
Completed
Conditions
Infectious Mononucleosis
First Posted Date
2006-01-10
Last Posted Date
2011-10-27
Lead Sponsor
University of Minnesota
Target Recruit Count
20
Registration Number
NCT00274404
Locations
🇺🇸

University of Minnesota Clinical Virology Clinic, Minneapolis, Minnesota, United States

Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding

Phase 2
Completed
Conditions
Herpes Genitalis
HIV Infection
First Posted Date
2005-09-12
Last Posted Date
2006-06-07
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Target Recruit Count
215
Registration Number
NCT00158509
Locations
🇧🇫

Service d'Hygiene du Centre Muraz, Bobo-Dioulasso, Burkina Faso

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

Phase 4
Completed
Conditions
Herpes Genitalis
Interventions
Drug: Valaciclovir
Drug: Placebo
First Posted Date
2005-09-12
Last Posted Date
2019-02-15
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
384
Registration Number
NCT00158860
Locations
🇨🇱

GSK Investigational Site, Santiago, Región Metro De Santiago, Chile

A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons

First Posted Date
2005-09-12
Last Posted Date
2008-01-10
Lead Sponsor
University of Washington
Target Recruit Count
60
Registration Number
NCT00161434
Locations
🇺🇸

Virology Research Clinic, Seattle, Washington, United States

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

Phase 4
Completed
Conditions
Infections, Herpesviridae
Interventions
Drug: Valaciclovir
Drug: Placebo
First Posted Date
2005-07-01
Last Posted Date
2018-02-12
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
73
Registration Number
NCT00116844
Locations
🇺🇸

GSK Investigational Site, Seattle, Washington, United States

Valacyclovir in Immunocompromised Children

Phase 1
Completed
Conditions
Shingles
Bone Marrow Transplantation
Interventions
Drug: Valacyclovir
First Posted Date
2003-04-30
Last Posted Date
2020-03-04
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
37
Registration Number
NCT00059592
Locations
🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

🇺🇸

Texas Children's Hospital, Houston, Texas, United States

Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation

Phase 3
Completed
Conditions
Cancer
First Posted Date
2003-01-27
Last Posted Date
2010-09-21
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT00045292
Locations
🇺🇸

Baylor University Medical Center, Dallas, Texas, United States

🇺🇸

Huntsman Cancer Institute, Salt Lake City, Utah, United States

🇺🇸

UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States

and more 3 locations

A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients

Phase 2
Completed
Conditions
Neoplasms
First Posted Date
2002-08-01
Last Posted Date
2015-08-24
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
30
Registration Number
NCT00042328
Locations
🇺🇸

Texas Children's Hospital, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy